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of Heteroresistant Vancomycin-Intermediate
Staphylococcus aureus Bacteremia in a Teaching Hospital
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Marı´a Beatriz Lasala,3 Susana Garcı´a,2 Carlos Vay,2 Angela Famiglietti,2 and Marta Mollerach1
The emergence of vancomycin intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA)
is of major concern worldwide. Our objective was to investigate the prevalence, phenotypic and molecular
features of hVISA strains isolated from bacteremic patients and to determine the clinical significance of the
hVISA phenotype in patients with bacteremia. A total of 104 S. aureus blood isolates were collected from a
teaching hospital of Argentina between August 2009 and November 2010. No VISA isolate was recovered, and
3 out of 92 patients (3.3%) were infected with hVISA, 2 of them methicillin-resistant S. aureus (MRSA) (4.5%
of MRSA). Macro Etest and prediffusion method detected 3/3 and 2/3 hVISA respectively. Considering the type
of bacteremia, the three cases were distributed as follows: two patients had suffered multiple episodes of
bacteremia (both hVISA strains recovered in the second episode), while only one patient had suffered a
single episode of bacteremia with hVISA infection. MRSA bloodstream isolates exhibiting the hVISA phe-
notype were related to HA-MRSA Cordobes clone (ST5-SCCmec I-spa t149) and MRSA Argentinean pediatric
clone (ST100-SCCmec IVNV-spa t002), but not to CA-MRSA-ST30-SCCmec IV-spa t019 clone that was one of
the most frequent in our country. Although still relatively infrequent in our hospital, hVISA strains were
significantly associated with multiple episodes of bacteremia ( p= 0.037) and genetically unrelated.
Introduction
Staphylococcus aureus is a common pathogen associ-ated with soft tissue infections, and more severe infections
such as endocarditis, osteomyelitis, and bloodstream infections.
The therapeutic choice in severe infections is often vanco-
mycin, especially for methicillin-resistant S. aureus (MRSA).
Since 1997, when the first strains with reduced suscepti-
bility to vancomycin intermediate S. aureus (VISA) were
reported in Japan,17 there has been an increasing concern
about the emergence of this phenotype around the world.
Heterogeneous VISA (hVISA) are defined as strains with
minimal inhibitory concentrations (MICs) in the susceptible
range (MIC £2mg/ml), but containing subpopulations of cells
in the vancomycin-intermediate range (VISA, MIC 4–8mg/
ml).6 These strains have been described for both MRSA and
methicillin-susceptible S. aureus (MSSA) respectively.1,35
hVISA strains appear to be an early stage in the de-
velopment of VISA and have been related to persistent
bacteremia, greater rates of complications, and vanco-
mycin treatment failure. Some authors consider that this
phenotype could be responsible for treatment failure,
whereas others have proposed that it has arisen as a
consequence of treatment failure and prolonged vanco-
mycin exposures.18
As hVISA strains enter the susceptible range by MIC
conventional methods such as microdilution, clinical
laboratory detection is very difficult. So far, the gold
standard is the population analysis profile-area under the
curve (PAP-AUC) method, but it is cost- and time con-
suming, and labor intensive. Other methods such as macro
Etest and screening plates have been described but none
of them has the sensitivity and specificity of the PAP-
AUC method.20
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The prevalence of hVISA varies depending on the geo-
graphic location, the population under study and the meth-
odology applied.29,34,46 Because of the multiplicity of tests
and the lack of standardized procedures, it is difficult to
compare results between studies. There has been special in-
terest in vancomycinMIC creep and treatment outcomes over
the years.18,22,37 Recently, we have reported a case of endo-
carditis due to hVISA infection in the Hospital de Clı´nicas
Jose´ de San Martı´n, a teaching hospital of Buenos Aires,
Argentina.35 A few months later, in the same institution,
another hVISA appeared, generating concern (described in
XX-Congreso Latinoamericano deMicrobiologı´a;Montevideo-
2010, unpublished data). The Hospital de Clı´nicas Jose´ de
San Martı´n is a 500-bed general hospital, is the main hospital
of the University of Buenos Aires, and receives patients
from all over the country. Despite the few cases reported in
Argentina,35,42,43 the prevalence, molecular epidemiology,
and clinical significance of hVISA strains in our country are
unknown because no standardized epidemiological studies
have been performed. This information is necessary to decide
the antibiotic therapy in patients with long-term vancomycin
treatment. It is also necessary to have an appropriate method
or a combination of methods suitable for accurate and easier
detection of hVISA in clinical settings.
This study had three main objectives: (i) to define the
prevalence and evaluate different methods to detect the
hVISA phenotype among S. aureus bacteremia in a teaching
hospital; (ii) to evaluate the genotypic characteristics of
MRSA bloodstream isolates exhibiting the hVISA pheno-
type, and (iii) to assess the clinical significance of the
hVISA phenotype in patients with bacteremia by S. aureus.
Materials and Methods
Isolates and study design
A prospective observational study was designed to eval-
uate the prevalence, phenotypic and molecular features of
hVISA strains from all S. aureus isolates recovered from
bloodstream infections at Hospital de Clı´nicas Jose´ de San
Martı´n, between August 2009 and November 2010. Only
one isolate from each patient was included in the analysis,
but isolates from subsequent blood samples obtained from
patients with multiple episodes of bacteremia were also
stored for vancomycin susceptibility testing. Persistent
bacteremia was defined as that lasting 7 days or more, de-
spite administration of antibiotic to which the isolate was
susceptible to in vitro, whereas recurrent bacteremia was
defined as the return of S. aureus subsequent to documen-
tation of negative blood cultures or clinical improvement,
after completing a course of antistaphylococcal therapy. The
study was approved by the Institutional Review Board.
All blood cultures were analyzed using BacT/ALERT
(BioMerieux, Inc., Durham, NC) and all S. aureus isolates
were identified by standard methods.
Susceptibility testing
MIC to antimicrobial agents (oxacillin, cefoxitin, genta-
micin, erythromycin, clindamycin, tetracycline, trimethoprim/
sulfamethoxazole, ciprofloxacin, tigecycline, rifampicin, van-
comycin, teicoplanin, and linezolid; all from Sigma-Aldrich,
St Louis, MO) was determined by the agar dilution procedure
using Mueller-Hinton agar (MHA; Difco BD, Sparks, MD)
according to Clinical and Laboratory Standards Institute
(CLSI) guidelines. Inducible clindamycin resistance in isolates
displaying erythromycin resistance was detected by the D-test
according to the recommendations of the CLSI.
Additionally, vancomycin MIC was determined by Etest
(AB BioMerieux, Solna, Sweeden) according to the manu-
facturer’s instructions.
CLSI interpretation criteria were used for all antimicro-
bial agents except for tigecycline, for which FDA/EUCAST
breakpoints were used.6
Screening for hVISA
All clinical isolates recovered in the study (n = 104) were
screened for hVISA and those positive by more than one
method were confirmed by PAP-AUC. S. aureus Mu3
(hVISA), Mu50 (VISA), and ATCC 29213 (vancomycin-
susceptible S. aureus [VSSA]) were used as control strains
in all the experiments. Mu3 and Mu50 were obtained from
the Network on Antimicrobial Resistance in S. aureus
(NARSA) strain collection. The screening methods included
were as follows:
(a) Screening plates: BHIV3, BHIV4, BHIV5, BHIV6
(Brain Heart Infusion agar [BHI; Difco BD] con-
taining 3, 4, 5, and 6 mg/ml vancomycin respectively),
and MHAT5 (MHA containing 5 mg/ml teicoplanin)
were assayed as previously described using 10 ml26
but also 1ml of bacterial suspensions equivalent to 0.5
McFarland for BHI screening plates, and equivalent
to 2.0 McFarland for MHAT5 screening plates. Plates
were incubated for 48 hr at 35C and growth was
considered as a positive result at any condition.
(b) Macro Etest: Inoculum was prepared from overnight
growth on blood agar plate; 200ml of bacterial suspen-
sion in saline solution equivalent to a 2.0McFarlandwas
plated and streaked onto BHI agar and vancomycin
Etest strips (AB BioMerieux) were applied. Plates
were incubated for 48 hr at 35C and values above or
equal to 6mg/ml were considered as a positive result.20
(c) Prediffusion method: Vancomycin 30mg and teicopla-
nin 30mg Neo-Sensitabs tablets (Rosco Diagnostica,
Taastrup, Denmark) were prediffused for 2 hr on MHA
plates, and after removing the tablets, the plates were
maintained at room temperature for 18 hr. A bacterial
suspension equivalent to a 0.5McFarland inoculumwas
streaked. Plates were incubated for 24 hr at 35C. The
results were interpreted following the manufacturer’s
recommendation: vancomycin inhibition zone diame-
ter £ 22mm and/or teicoplanin inhibition zone diame-
ter < 20mm were considered as a positive result.23,38
PAP-AUC method
PAP-AUC was performed for strains displaying at least
two positive results on different screening assays/screening
media. Briefly, serial 10-fold dilutions of cultures were
plated onto increasing concentrations of vancomycin BHI
agar (0, 0.25, 0.5, 1, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, and 10mg/ml)
(Difco BD). Colony growth at 48 hr was counted and viable
count (log10 CFU/ml) was plotted against vancomycin
concentration using GraphPad Prism Software. S. aureus
26 DI GREGORIO ET AL.
ATCC 29213 (VSSA), Mu50 (VISA), and Mu3 (hVISA)
were included. The AUC was measured for each sample and
the ratio of test isolate AUC/mean Mu3 AUC was calcu-
lated. As described by Wootton et al., the criteria to define
hVISA and VSSA were a PAP/AUC ratio ‡ 0.90 and a PAP/
AUC ratio < 0.90 respectively.49
PCR identification of mecA, lukS/F-PV, SCCmec,
and agr types
Detection of mecA and PVL encoding genes (lukS/F-PV)
was attempted after extraction of genomic DNA for all MRSA
isolates as previously described.47 SCCmec types were deter-
mined by PCR with a simplified version of Kondo’s typing
system, includingM-PCR-1 andM-PCR-2.25 In specific cases,
SCCmec typing was performed as recommended by Oliveira
and de Lencastre,33 and SCCmec IVNV characterization using
primers described by Sola et al.43
The agr locus was genotyped by multiplex PCR, as pre-
viously described.15
Genetic analysis by pulsed-field gel electrophoresis,
multilocus sequence typing, and spa typing
Genotyping analysis was conducted using pulsed-field gel
electrophoresis (PFGE) with SmaI, as previously described.5
The PFGE fingerprints were compared by the unweighted
pair-group method with arithmetic mean (UPGMA) clus-
tering analysis, applying the Dice correlation coefficient.
MRSA clones previously described in Argentina were in-
cluded in the PFGE pattern analysis.8,13,41 Multilocus se-
quence typing (MLST) was performed for representative
isolates of the main pulsotypes.7 Confirmed hVISA strains
were also studied by spa typing16 and MLST.
Statistical analysis
p-Values were calculated by w2 Yates test and Fisher’s
exact test for categorical variables. A p-value < 0.05 was
considered significant.
Results
Antimicrobial susceptibility and molecular
characterization of isolates
Forty-eight out of the 92 (52.2%) patients with S. aureus
bacteremia included in the study were infected by MSSA,
whereas 44 (47.8%) were infected by MRSA. Table 1
compares the antimicrobial resistance rates of MSSA and
MRSA among S. aureus blood isolates. MRSA isolates were
more likely to be resistant to gentamicin, erythromycin/
clindamycin, and ciprofloxacin ( p < 0.0001). As revealed by
the D-test, in the MSSA group, 9/9 erythromycin-resistant
isolates displayed inducible clindamycin resistance. By
contrast, in the MRSA group, only 5/26 erythromycin-
resistant isolates displayed the inducible phenotype, 1/26
was negative by the D-test, and the remaining isolates (20/
26) showed constitutive clindamycin resistance. All isolates
were susceptible to linezolid, tigecycline, vancomycin, and
teicoplanin.
The molecular characterization of the MRSA group re-
vealed 43/44 isolates harboring the mecA gene. The most
frequent SCCmec types were SCCmec I and IV (41.8%
and 39.5% respectively) and the most frequent agr group
among them was the agr group II (53.5%). Only 13/44
(29.5%) harbored the PVL coding genes (lukS/F-PV), and
all PVL-positive isolates also harbored SCCmec IVc or
SCCmec IVa.
PFGE analysis revealed that 14/18MRSA isolates carrying
SCCmec I corresponded to the Cordobe´s clone (pulsotype D-
ST5-SCCmec I).12,41Most isolates carrying SCCmec IVwere
related to the main community-acquiredMRSA (CA-MRSA)
clones described in Argentina: pulsotype C (ST30-SCCmec
IVc) and pulsotype A (ST5-SCCmec IVa) (nine and five
isolates respectively) (Table 2).8,11,13,31,43
Vancomycin susceptibility and prevalence of hVISA
Vancomycin susceptibility analysis included 104 clinical
isolates recovered from 92 patients with one or more
Table 1. Antimicrobial Resistance Rates of Methicillin-Susceptible S. aureus
and Methicillin-Resistant Staphylococcus aureus Among S. aureus Blood Isolates
MSSA (n = 48) MRSA (n = 44)
(lg/ml) (lg/ml)
Antimicrobial
agent Range MIC50 MIC90 %R
a Range MIC50 MIC90 %R
a p-Value
Gentamicin 0.063 to 128 0.25 32 12.5 < 0.063 to > 512 32 > 512 61.4 < 0.0001
Erythromycin 0.125 to > 512 0.25 > 512 18.75 0.125 to > 512 > 512 > 512 59 0.0002
Clindamycin < 0.063 to 0.125 < 0.063 0.063 18.75 < 0.063 to > 512 0.063 > 512 56.8 0.0004
Tetracycline 0.063 to 1 0.25 0.5 0 0.063 to 64 0.125 0.5 4.5 0.23
TMP-SMX 0.25 to 1 1 1 0 0.25 to > 512 1 2 4.5 0.23
Ciprofloxacin 0.063 to 8 0.25 1 8.3 0.063 to 256 8 64 59 < 0.0001
Tigecycline 0.125 to 1 0.25 0.5 0 0.063 to 1 0.25 1 0 —
Rifampicin < 0.002 to 0.008 0.004 0.016 0 < 0.002 to 2 0.008 0.5 9.1 0.05
Vancomycin 0.5 to 2 1 1 0 0.5 to 2 1 1 0 —
Teicoplanin 0.25 to 4 0.5 1 0 0.125 to 2 1 1 0 —
Linezolid 1 to 4 2 2 0 1 to 2 2 2 0 —
a%R, percentage of resistant isolates.
MIC, minimal inhibitory concentration; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; TMP-SMX,
trimethoprim/sulfamethoxazole.
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episodes of bacteremia by S. aureus. Eleven patients had
suffered multiple episodes of bacteremia (2 of them suffered
persistent bacteremia and 9 recurrent bacteremia).
No VISA (vancomycin MIC from 4 to 8 mg/ml) or
vancomycin-resistant (MIC ‡ 16 mg/ml) S. aureus strains
were detected by agar dilution MIC or Etest. All isolates
were susceptible to teicoplanin with MIC £ 4 mg/ml. By agar
dilution, vancomycinMIC90was 1mg/ml (range 0.5–2mg/ml),
while by the Etest, MIC90 was 1.5mg/ml (range 0.38–2mg/ml).
Eleven isolates were considered to be hVISA because they
were positive by at least two screening assays (including
screening plates,Macro Etest, and prediffusionmethods), and
subsequently analyzed by the PAP-AUC method. Only three
were confirmed as hVISA. Two hVISA strains were MRSA,
while the other was a MSSA strain (Table 3). All hVISA
isolates displayed Etest MIC > 1 mg/ml.
Twenty-seven isolates grew on at least one screening
assay/medium. Screening plates were tested with two dif-
ferent inocula. Using 10ml (0.5 McFarland for BHI
screening plates and 2.0 McFarland for MHAT5 screening
plates), we found 19 positive isolates with MHAT5 (one of
them confirmed as hVISA), 15 positive isolates with BHIV3
(two of them confirmed as hVISA), and 2 positive isolates
with BHIV4. On the other hand, using 1 ml, only one isolate
was positive with MHA5T and three with BHIV3 (one of
them confirmed as hVISA). No single isolate was positive
with BHIV5 or BHIV6 at any condition.
The macro Etest successfully detected 3/3 hVISA isolates,
whereas the prediffusion method detected four presumable
hVISA, being only two confirmed by PAP-AUC (Table 3).
Clinical, microbiological, and molecular evaluation
of hVISA bacteremias
Three out of the 92 (3.3%) patients suffering bacteremia
at Hospital de Clı´nicas during 2009–2010 had hVISA.
Considering the type of bacteremia, the three cases were
distributed as follows: 2/11 patients had suffered multiple
episodes of bacteremia (both hVISA strains recovered in the
second episode), while only 1/81 patients had suffered a
single episode of bacteremia with hVISA infection. These
results indicate that hVISA isolation was significantly as-
sociated with multiple episodes of bacteremia ( p= 0.037).
In patient 1, isolates were recovered from persistent
bacteremia. The patient suffered endocarditis secondary to a
catheter-related bacteremia, and did not undergo surgery.
The patient had no prior S. aureus infection and no history
of treatment with vancomycin. Isolate 55703 (hVISA) was
recovered after vancomycin treatment, and exhibited a
higher PAP/AUC ratio than the first blood culture isolate
(55603, VSSA). By contrast, patient 2 had prior S. aureus
infection and history of vancomycin treatment. This case
was a recurrent bacteremia and isolate 55343 was recovered
from blood culture without a known source. Isolate 55576
(hVISA) was recovered after vancomycin treatment failure,
and also exhibited a higher PAP/AUC than the first isolate
(55343, VSSA). Both patients 1 and 2 died. The clonality of
the isolates recovered before and after vancomycin treat-
ment was demonstrated by PFGE (Fig. 1). In patient 3, the
isolate recovered (53079) corresponded to a MSSA single
bacteremia secondary to parotiditis, which, after treatment
with b-lactams, had a good clinical outcome.
As revealed by MLST, PFGE macrorestriction analyses,
and spa typing, hVISA strains were genetically unrelated
(Table 4). Isolate 55703 (ST5-SCCmec I-agr II, luk-PV
negative) was characterized as spa t149-pulsotype D, re-
vealing that this isolate is a subtype of the Cordobe´s clone,
previously described as prevalent in this hospital.12 Isolate
55576 (ST100-SCCmec IVNV, -agr II-luk-PV negative) was
spa t002-pulsotype B, had a Tn4001 insertion into the class
B mec complex, and is related to the Argentine pediatric
clone.43 Isolate 53079 was MSSA spa t267 and belonged to
ST97, a sequence type predominant in bovines with mastitis
and also described in Argentina causing osteomyelitis.28
Discussion
In this study, we describe for the first time the prevalence
and molecular characterization of hVISA isolates in a
teaching hospital of Buenos Aires (Argentina) during 2009–
2010. No VISA isolate was recovered, and the rate of
hVISA was 3.3% of the S. aureus bloodstream infections
(4.5% of MRSA). This is a low prevalence value when
compared with results obtained by other researchers. In an
Italian multicenter surveillance study conducted between
2007 and 2009, the frequency of hVISA was 19.5%.3 A
Table 2. Methicillin-Resistant S. aureus Clones Detected According to SCCmec Type,
Pulsed-Field Gel Electrophoresis, and Multilocus Sequence Typing
SCCmec type No. of isolates PFGE pulsotype STa Clonally related clone
I 14 D 5 Cordobe´s clone (ST5-I)
4 Other NDb ND
IVc 9 C 30 Southwest Pacific clone (ST30-IV)
IVa 5 A 5 CAA clone (ST5-IV)b
IVNV
c 2 B 100 Pediatric clone (ST100-IV)
IVvar
d 1 E 72 USA700
V 2 Other ND ND
III 1 Other ND ND
NT 5 Other ND ND
aST, sequence type. ST was determined for one representative isolate of each PFGE pulsotype.
bCAA clone (ST5-IV), community-acquired MRSA described in Argentina (PFGE A, ST5-IV).13
cIVNV, Tn4001 was detected integrated into the class B mec complex.
dIVvar, tnp20 was detected integrated into the class B mec complex.
ND, not determined; NT, not typeable; PFGE, pulsed-field gel electrophoresis.
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higher rate (47.8% of MRSA) was reported by Horne at
Austin Hospital (Australia) during 2005–2006 considering
all clinical specimens.19 However, the rate found in our
study is similar to that described for blood culture isolates in
Taiwan.29
As reviewed by Howden et al., changes in hVISA can
occur over time within specific institutions.20 In Argentina,
hVISA strains were described in 2009 for the first time, one
of them in our institution (Hospital de Clı´nicas).35,42 Con-
sidering the changing epidemiology of S. aureus and the
impact of local antibiotic use politics it is difficult to predict
future trends; so further surveillance epidemiological studies
in this center as well as in other institutions of our country
need to be conducted.
The selection of an optimal laboratory screening test for
hVISA remains to be difficult. Difficulties are mainly based
on the differences experienced by researchers in terms of
specificity, sensitivity, and population under study. Different
screening plates have been extensively studied in terms of
specificity and sensitivity,20 but ultimately all presumable
hVISA isolates should be confirmed by PAP-AUC. In our
hands, none of the screening plates detected all three hVISA
described in this study. BHIV3 detected two of them, but, as
previously described, it has a high false positive rate.26 Two
isolates were detected as presumable hVISA by MHAT5
and teicoplanin prediffusion tablets, but not by vancomycin-
based screening tests, and PAP-AUC revealed that these
isolates were not hVISA. Isolates exhibiting a reduction in
teicoplanin susceptibility may not always display a reduc-
tion in vancomycin susceptibility.
Macro Etest has been proposed as an accurate method
to detect hVISA. Surprisingly, while the manufacturer’s
breakpoint is 8 mg/ml, the highest value among all clinical
isolates recovered in our study, including the three hVISA
strains was 6 mg/ml. Only one isolate, which was not con-
firmed as hVISA by PAP-AUC, exhibited macro Etest result
of 6 mg/ml, and was negative by other screening tests (data
not shown). The prediffusion method has been described for
the detection of colistin-resistance, daptomycin-nonsusceptible
strains, and the hVISA/VISA phenotype.2,23,32 Although this
screening method is not expensive and might represent a
simpler alternative for hVISA detection in clinical labora-
tories, it has not been extensively evaluated. Despite the
two false positives, we had acceptable results with the
prediffusion method (2/3 hVISA isolates detected).
Our results show thatmacro Etest with a breakpoint ‡ 6mg/
ml (lower than the value proposed by themanufacturer) could
FIG. 1. Population analysis profile and pulsed-field gel
electrophoresis of the heterogeneous vancomycin interme-
diate Staphylococcus aureus (hVISA) strains recovered
from multiple episodes of S. aureus bacteremia.  ATCC
29213, , Mu3, and : Mu50. (a) Isolates recovered from
patient 1: 7 55603 (first isolate, A1, population analysis
profile-area under the curve [PAP-AUC] ratio: 0.73) and ;
55703 (isolate recovered after vancomycin treatment, A2,
PAP-AUC ratio: 1.05). (b) Isolates recovered from patient
2: )55343 (first isolate, B1, PAP-AUC ratio: 0.47) andA
55576 (isolate recovered after vancomycin treatment, B2,
PAP-AUC ratio: 0.96).
Table 4. Genotyping of Heterogeneous Vancomycin Intermediate S. aureus Isolates
and Main Methicillin-Resistant S. aureus Clones Described in Argentina
Strain SCCmec Allelic profile (arc-aro-glp-gmk-pta-tpi-yqi) ST CC spa type
55703 (hVISA) I 1-4-1-4-12-1-10 5 5 t149
55576 (hVISA) IVNV 1-65-1-4-12-1-10 100 5 t002
53079 (hVISA) — 3-1-1-1-1-5-3 97 97 t267
Cordobe´s clone I 1-4-1-4-12-1-10 5 5 t149
CAA clonea IVa 1-4-1-4-12-1-10 5 5 t311
Southwest Pacific clone IVc 2-2-2-2-6-3-2 30 30 t019
aCAA clone, community-acquired MRSA described in Argentina (PFGE A, ST5-IV).14
CC, clonal complex.
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be used to predict likelihood of hVISA in laboratories where
PAP-AUC testing is not performed routinely, especially in
cases of persistent/recurrent bacteremia. Alternatively, pre-
diffusion method should be considered a very good option as
the cost of the tablets is comparatively convenient.
The three hVISA isolates identified in this study pre-
sented vancomycin MIC values ‡ 1.5 mg/ml by the Etest. In
agreement with various reports, hVISA isolates displayed
vancomycin Etest MIC values close to the breakpoint (2mg/
ml) and higher than those determined by the agar dilution
method.36,39 Additionally, two of the three cases were as-
sociated with mortality. The role of vancomycin in the
treatment of high but susceptible vancomycin MIC isolates
of MRSA has raised controversial discussions. Several
studies have explored the clinical significance of vanco-
mycin MIC in S. aureus infections and have demonstrated
episodes of vancomycin treatment failure with a high MIC
( ‡ 1.5 mg/ml by the Etest).44,45,48 By contrast, others authors
observed no association of mortality with increasing van-
comycin MICs.27,40 However, treatment recommendations
continue to support vancomycin for MRSA bacteriemia for
isolates with vancomycin MIC values £ 2 mg/ml, and
changes to therapy should be guided by the patient’s clinical
response.30
One MRSA isolate was mecA negative and mecC nega-
tive (data not shown), suggesting that the mechanism re-
sponsible for b-lactam resistance might be b-lactamase
hyperproduction or changes in affinity of penicillin-binding
proteins.
Although the hVISA phenotype has been described
mainly from MRSA, it has also been reported from MSSA
strains.1,14,35 Our results revealed that 2/3 cases were
MRSA and 1/3 MSSA strains, all of them presenting dif-
ferent genotypes. Therefore, hVISA strains recovered
during the study period are not clonally related, indicating
that this emergence is the result of independent genetic
events. By contrast, other surveillance studies have dem-
onstrated hVISA clonal dissemination with higher preva-
lence values.14
The two MRSA hVISA strains belong to clonal complex
5, one of them related to HA-MRSA Cordobe´s clone (ST5-
SCCmec I) and the other to the Argentine pediatric clone
(ST100-SCCmec IVNV). Clonal complex 5 is widely dis-
tributed in Argentina and also around the world.4,9,10,43 It
has been described that this genotype has an extraordinary
genomic plasticity, which might explain the large proportion
of hVISA, VISA and all the VRSA strains belonging to this
lineage.21,24
Although the ST30-SCCmec IVc-pulsotype C clone, re-
cently described as the main cause of CA-MRSA infections
in Argentina,8,31 was the most frequent CA-MRSA clone
recovered in this study, we found no hVISA strains be-
longing to this lineage. To our knowledge, only one hVISA
strain has been described within Clonal Complex 30, car-
rying SCCmec I.21
Regarding the clinical significance of these strains, in this
study we found a significant association between hVISA
phenotype and multiple episodes of bacteremia. In addition,
2/3 hVISA were MRSA strains recovered from persistent/
recurrent bacteremias and selected after vancomycin treat-
ment. As reviewed by Howden et al.,20 the emergence of
hVISA after vancomycin therapy has been reported by
several authors. Therefore, the presence of this phenotype
should be considered in face of patients with these clinical
situations. However, one hVISA isolate was recovered from
a MSSA bacteremia not treated with vancomycin. Related to
this, in a retrospective study, Yamakawa et al. reported the
emergence of hVISA before vancomycin introduction in
Japan.50
Limitations of this work should be mentioned. The small
number of hVISA isolated in this study are insufficient to
generalize conclusions about the appropriate screening
methods for the detection of this phenotype and our obser-
vations have to be corroborated with a higher number of
strains by further surveillance studies in Argentinean clini-
cal settings. Nevertheless, these results constitute an im-
portant contribution to phenotypic, genetic, and clinical
knowledge of hVISA, especially considering that most of
the published reports originate from developed nations, and
data from Latin American countries are grossly underrep-
resented. Nonetheless, further epidemiological surveillance
in Argentinean settings is required for a better understanding
of this phenomenon and its evolution.
Conclusions
This study makes several key observations. We describe
for the first time the prevalence and molecular character-
ization of hVISA isolates in a teaching hospital of Buenos
Aires (Argentina). The hVISA phenotype occurred in 3.3%
of the S. aureus bloodstream infections and no VISA isolate
was recovered. Even if the prevalence is still relatively low
compared to other studies, the clinical impact is concerning
as a significant association between hVISA phenotype and
multiple episodes of bacteremia isolates was determined.
The majority of reported hVISA and VISA isolates evolved
from MRSA strains, nevertheless in this study 1/3 hVISA
were detected among MSSA isolates, consequently this re-
sult highlight the importance of screening hVISA phenotype
in MSSA isolates as in MRSA.
The results of molecular typing indicate that the hVISA
isolates were genetically diverse. The two methicillin-
resistant hVISA isolates belong to MRSA clones previously
disseminated in Argentina.
In addition, our results show that the combination of Etest
MIC > 1 mg/ml, macro Etest value ‡ 6 mg/ml, and the pre-
diffusion method could be considered in future studies as
useful strategies to predict likelihood of hVISA in labora-
tories where PAP-AUC testing is not performed routinely,
especially in cases of persistent/recurrent bacteremia.
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